Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023
SKU ID :TNV-14069936 | Published Date: 08-Oct-2019 | No. of pages: 153Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• ACE inhibitors - Market size and forecast 2018-2023
• ARBs - Market size and forecast 2018-2023
• Other therapeutics - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Introduction of smartphone-based diagnosis and treatment.
• Advent of novel therapies
• Increasing awareness about renal disorders
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: ACE inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: ACE inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 22: ARBs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: ARBs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of the total population)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Prevalence/incidence of associated risk factors of proteinuria
Exhibit 46: Growth of geriatric population 2009-2018 (%)
Exhibit 47: Side effects of ACE inhibitors used for the treatment of proteinuria
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AbbVie Inc. - Vendor overview
Exhibit 55: AbbVie Inc. - Business segments
Exhibit 56: AbbVie Inc. - Organizational developments
Exhibit 57: AbbVie Inc. - Geographic focus
Exhibit 58: AbbVie Inc. - Key offerings
Exhibit 59: AbbVie Inc. - Key customers
Exhibit 60: AstraZeneca Plc - Vendor overview
Exhibit 61: AstraZeneca Plc - Business segments
Exhibit 62: AstraZeneca Plc - Organizational developments
Exhibit 63: AstraZeneca Plc - Geographic focus
Exhibit 64: AstraZeneca Plc - Key offerings
Exhibit 65: AstraZeneca Plc - Key customers
Exhibit 66: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 67: Boehringer Ingelheim International GmbH - Business segments
Exhibit 68: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 69: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 70: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 71: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 72: Boehringer Ingelheim International GmbH - Key customers
Exhibit 73: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 74: Bristol-Myers Squibb Co. - Business segments
Exhibit 75: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 76: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 77: Bristol-Myers Squibb Co. - Key offerings
Exhibit 78: Bristol-Myers Squibb Co. - Key customers
Exhibit 79: Merck & Co. Inc. - Vendor overview
Exhibit 80: Merck & Co. Inc. - Business segments
Exhibit 81: Merck & Co. Inc. - Organizational developments
Exhibit 82: Merck & Co. Inc. - Geographic focus
Exhibit 83: Merck & Co. Inc. - Segment focus
Exhibit 84: Merck & Co. Inc. - Key offerings
Exhibit 85: Merck & Co. Inc. - Key customers
Exhibit 86: Novartis AG - Vendor overview
Exhibit 87: Novartis AG - Business segments
Exhibit 88: Novartis AG - Organizational developments
Exhibit 89: Novartis AG - Geographic focus
Exhibit 90: Novartis AG - Segment focus
Exhibit 91: Novartis AG - Key offerings
Exhibit 92: Novartis AG - Key customers
Exhibit 93: Pfizer Inc. - Vendor overview
Exhibit 94: Pfizer Inc. - Business segments
Exhibit 95: Pfizer Inc. - Organizational developments
Exhibit 96: Pfizer Inc. - Geographic focus
Exhibit 97: Pfizer Inc. - Segment focus
Exhibit 98: Pfizer Inc. - Key offerings
Exhibit 99: Pfizer Inc. - Key customers
Exhibit 100: Sanofi - Vendor overview
Exhibit 101: Sanofi - Business segments
Exhibit 102: Sanofi - Organizational developments
Exhibit 103: Sanofi - Geographic focus
Exhibit 104: Sanofi - Segment focus
Exhibit 105: Sanofi - Key offerings
Exhibit 106: Sanofi - Key customers
Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 117: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 118: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
Tables & Figures
Companies
AbbVie Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
- PRICE
-
$2500$4000